first for afternoon. XXXX Good for our update quarter call. you us joining And corporate thank
program. an We our clinical technology on platform will muscular our and our Duchenne dystrophy program, begin with update followed by on today an update COVID-XX exosome
over next are and updates these several looking months. important of forward several programs have multiple key We each events we the to on
the which DMD dystrophy year cell on of a positive well in limb, with It muscle was CAP-XXXX therapy boys trial are the our we Let men them. products being over DMD. population or trial, of our X non-ambulant year We Current and randomized understand disease States, improvements to young CAP-XXXX. point advanced potentially be our size from per Duchenne as young focused with update as cardiac on administered for DMD. XX,XXX in reported half U.S. trial to were eligible important function. envision and estimates me HOPE-X placebo-controlled to approximately as with non-ambulant. over available the double-blind II who This program. clinical for CAP-XXXX an improvement patients saw CAP-XXXX and skeletal to There was boys times and Phase the One no muscular who If topline approved, with this data and limited DMD may non-ambulant ago, in primarily is upper other options have United market begin years. many men we older
quarter CAP-XXXX partner we it safely our strength of cell patients, for manufacturing provides several early expertise cell given over has This DMD world on commercializing in and a commercial this therapy who been of with past ready track we our data Over product of years, over the CAP-XXXX commercialization record which and operate safety for with robust late-stage capacity desire offices than more in class and countries has collaboration a commercialization. and to DMD and of XXX to first be to efficacy Based therapy a other data to CAP-XXXX employees. patients manufacturing Lonza should and ability and to-date. us Lonza, the The be the gathered manufacturer for our time the has and XX approved, announced XX with approximately development have year, the in collaboration of and to company clinical CAP-XXXX for sites an trials full biologics. XX,XXX Lonza XXX indications. collaboration established potential aims expand potential for in
Now on And today that exciting. key update I the would you have like events for DMD forward to very CAP-XXXX and several be to occurred continues path recently.
data end, the product. towards our First, our data, we FDA to which have path therapeutic preferred expedited submitted based regarding this accelerate warranted. path RMAT a an And HOPE-X to we of To the gene on to to the might sets complete path therapies, B requested based access that a ways DMD. the the designation, FDA explore to registration our for on registration have the based to cell work analysis. approval and for this package data We new clinical allows to to and meeting on of be expedited we believe and continue registration discussions with Type strength for pathway continue
do that we recognize requirements that Now discussions in optimistic, To clinical another are remain while engaged and will parties keep our for as the this program by we may their on in We various as for we end, program FDA remain progress anticipate opportunity firm third clarity we further regarding front partnership well. potential you with a trial. quarter. on this this updated to
exosomes, talk vaccine shifting moment, about gears a for for and SARS-CoV-X our Now, commonly specifically, our let’s called COVID-XX.
our a for SARS-CoV-X. candidate efforts vaccine develop to We novel continue
grateful Experts become from semi-annual the may emerging therefore, the variants to this global in While vaccines we so available working the that prolong the necessary even population, mRNA solved are combat well, annual is will predict by are means and issue. be no or virus. currently a endemic vaccines or COVID protection
to potentially the an as or available delivery Our aware provide that vehicle and are uses we development exosome approach, in today. is vaccine a which candidate alternative multivalent anything currently can of
or paves on This clinical opportunities of focus given use delivery vehicles, pipeline as on from the what exosomes whether multivalent drug and establish this we have to-date. has received an that stating, FDA for our ability recently their approval mRNA expanded diseases that we the done been to is the nanoparticles, our to the work vaccine. essentially our In of vehicles nature’s exactly lipid Based for for pathway is other the we pre-IND, us infectious through regulatory addition, believe delivery as necessary we vaccine product on exosomes of development exosome Part of submitted as feedback IND. to have for way therapeutic. the development feedback
as our can designing a We the be Phase are in idea currently are are vaccines, the of trial underway to Health U.S. vaccinated are vaccine and as addition of we this We a with believe still clinical IND as Based path population. important our I vaccine well that aiming available used of for strategies. National high we by Diseases, a with shown SARS-CoV-X with further we population tool quarter can the an provide naive in about booster, it and be speaking less the the and the likely of following Infectious to-date needing have vaccine will we of a in planned, may the to our exosomes have studies., an program, Institutes multiple has will that of percentage and than we fall with have year. prevention data been be toxic broader COVID-XX. third whom vaccine conversations submit lipid Since base Institute considering by nanoparticles been immunity Allergy on currently enabling potentially Capricor published the variants the the to and IND are that of the National part and proteins to
conducted Phase using and for exosomes designing a roadmap patients I future deliver this mRNA. are XX approximately vaccines be will provide trial to to and the product We in likely it
this will the that hopeful FDA are We support plan.
government Various will the vaccine partners to and of agency. approach the various are In potential currently compared time our or the vaccine. our addition, we initiation survey clinical will be available evaluate landscape to synergistic prior trial [ph] if our when trig by candidate beneficial as
will keep on We funding possible updated opportunities for this you program.
stay that So tuned well. as for please updates on
of Now be of of I’m our vaccine therapeutic agreement this a treat in technology. and to with rapid as worldwide we exclusive turning allows our focused also Hopkins support of and exosome portfolio of to advances the exosome to the a development the broad month, based platform the execution growth therapeutics vehicles going program. announced for of Johns to spectrum delivery University Earlier vaccines on Expansion our exosomes continues expansion diseases. license
lab new Dr. we to with expanding with high strengthen. intellectual relationship University Stephen continue a will which the at portfolio, into property throughput codifies innovative agreement license products Gould We opportunity have to an this Hopkins Johns the built translate science and of
relationship do together. we worked over Gould past have Dr. we work opportunities the more this create for the with will year, As based on licensing future
Lab, Now we our March, we about exosome talk engineered turning focused on are to a Capricor scientific leading exosome on we work, in program, focused the as the therapeutic can ongoing call company. the had in we of which is becoming some that
diseases. human target, -- mRNAs we RNAs our Our based engineered formulation potentially the of ultimate into goal generating and of loading and on preventionally on to exosomes and as prevent are treat exosomes first focus mentioned,
of We support out identified plan expansion quarters product INDs. we next have teams plan and over manufacturing been for indications focused few on core two our technology, R&D, our file have which to building to the and development to one to the
As began cell enrollment our in you patients with therapy II double-blind placebo-controlled is to severe COVID-XX Phase year. late a last of with up know, trial XX CAP-XXXX, we This product.
believe selective to benefit inclusion/exclusion CAP-XXXX. in been because our have patients want that from those We will treat we criteria, only we
patients targeted need not supplemental ventilated. are the and are you, but remind me the oxygen that hospital Let are those in
severe Benjamin considerably. paper many solutions from it seeing of for Our to anti-inflammatory. cells. The CAP-XXXX Many many COVID in from tissue words, an from We very Nature, treating to artificially prognosis COVID. once to CAP-XXXX save in by MX of of by showed give too for data point. from a the forward their a keep clinical cells for the other benefits available that as and ventilation, data patient filled are great other the therapeutic the year. that COVID quarter MX the patients. in early preclinical with suggests In me have profile. hope know off identified the lung because towards this terminal recent expression look findings his cases, ventilated expected of patients in these studies paper goal turns in that mechanism this this action worsens population inflammatory to them potential third data, We macrophages colleagues is I from A sick from are Journal is and change towards complication, exposome immune Izar our macrophages that patients
to next In positive, discuss Following in next key exciting development over receipt meet the multiple FDA the coming we step with to development. will with different and up summary, have levels data, at months. programs if ongoing of milestones several various of this plan we
in XXXX new & moving Gene to Cell the the regarding Earlier vaccines. tuned over on had and our able our in of to have into at our plans on the week, at Vesicle. the strategic on exosomes the to presenting announcement plans management opportunity million team execute $XX American opportunity We cash strengthening Therapy on and stay through of senior next for Please our SARS-CoV-X are working Extracellular execute to XXXX. International poster to today, And we be team. present we are to a Society Society use leaders
conference in DMD. in program at Additionally, plan discuss present June, data CAP-XXXX the to we to our PPMD
on our towards an and to with turn commercialization. publications on we the over progress key both peer in CFO, are we reviewed over I financial. a our CAP-XXXX making Lastly, to exosome and our pathway approval now and regarding pursuing for next be months programs. potential platform have AJ multiple review the the several by Bergmann, journal continue I announcements to several the update call expect for will with energized regards
